Lundbeck has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company’s lead investigational oral orexin 2 receptor (OX2R) agonist being developed for the treatment of narcolepsy. The designation marks a significant regulatory milestone for the company’s expanding pipeline of therapies targeting sleep-wake disorders.

Currently in Phase 1b clinical development, Lu AH69593 is one of several investigational compounds in Lundbeck’s neuroscience portfolio focused on addressing unmet needs in patients living with disorders that impair normal sleep and wakefulness.

Narcolepsy is a chronic neurological disorder that affects the brain’s ability to regulate sleep-wake cycles. Patients often experience excessive daytime sleepiness, sudden sleep attacks, disrupted nighttime sleep, sleep paralysis and hallucinations. Individuals with narcolepsy type 1 also experience cataplexy, a sudden loss of muscle tone triggered by strong emotions, significantly affecting daily activities and quality of life.

Lu AH69593 targets the orexin pathway, a key biological mechanism responsible for promoting wakefulness and maintaining stable sleep-wake regulation. The therapy is designed to activate the orexin 2 receptor, aiming to restore wakefulness by addressing the underlying biology of narcolepsy rather than simply managing its symptoms.

Commenting on the development, Johan Luthman, Executive Vice President, Research and Development, Lundbeck, said, “Fast Track designation is an important milestone for Lu AH69593 and for our ambition to translate compelling orexin biology into a new treatment approach for narcolepsy and other sleep-wake disorders. For people living with narcolepsy, the ability to sustain wakefulness can shape almost every part of daily life. The designation recognises the urgent need for innovative therapies and provides an opportunity to work closely with the FDA as we advance this programme.”

The FDA’s Fast Track programme is intended to facilitate the development and expedite the review of therapies that treat serious conditions and address unmet medical needs. The designation enables closer interaction with the agency throughout the development process and may support a more efficient regulatory pathway if clinical data continue to demonstrate promise.

Lu AH69593 is an investigational small-molecule therapy discovered by Lundbeck and is currently undergoing evaluation for its safety, tolerability, pharmacokinetics and pharmacodynamics in Phase 1b studies. The therapy has not yet been approved by any regulatory authority, and its efficacy and safety remain under investigation.

The Fast Track designation further strengthens Lundbeck’s strategy of advancing innovative treatments across neurology, neuroendocrinology and rare neurological disorders, while reinforcing the growing therapeutic potential of orexin-based medicines for sleep-wake disorders.